Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated Stock

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
422.8 USD +0.90% Intraday chart for Vertex Pharmaceuticals Incorporated +5.41% +3.91%
May. 10 Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone MT
May. 07 FOMO is Back Our Logo
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials (USD)

Sales 2024 * 10.77B Sales 2025 * 11.71B Capitalization 109B
Net income 2024 * 3.98B Net income 2025 * 4.48B EV / Sales 2024 * 8.83 x
Net cash position 2024 * 13.97B Net cash position 2025 * 19.01B EV / Sales 2025 * 7.7 x
P/E ratio 2024 *
27.9 x
P/E ratio 2025 *
24.9 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.89%
More Fundamentals * Assessed data

Chart Vertex Pharmaceuticals Incorporated

Dynamic Chart

Latest news about Vertex Pharmaceuticals Incorporated

Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone MT
FOMO is Back Our Logo
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating MT
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating MT
Vertex Pharmaceuticals Q1 Non-GAAP EPS, Revenue Increase MT
Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug DJ
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORATED Reports Q1 EPS $4.76, vs. Street Est of $4.06 MT
Vertex Pharmaceuticals Reiterates FY 2024 Total Product Revenue Guidance of $10.55-$10.75 Billion MT
More news

Latest transcript on Vertex Pharmaceuticals Incorporated

Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 06, 2024
More transcripts

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins... Our Logo
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511 MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430 MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating MT
More recommendations

Press releases Vertex Pharmaceuticals Incorporated

Vertex: Q1 Earnings Snapshot AQ
Vertex Reports First Quarter 2024 Financial Results BU
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older BU
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES PR
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES AQ
More press releases

News in other languages on Vertex Pharmaceuticals Incorporated

Compañías que se deben tener muy en cuenta por técnico este jueves en Wall Street
EE.UU. - Valores a seguir en Wall Street (actualizado)
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Nvidia, The Home Depot, Palantir, Target, Lowe's, Block, Rollins...
Le marché ressuscite le Fed Put
Borsa di Italia: Il mercato resuscita la "Fed Put"
More news

Quotes and Performance

1 day+0.90%
1 week+5.41%
Current month+7.63%
1 month+6.34%
3 months-0.03%
6 months+13.15%
Current year+3.91%
More quotes

Highs and lows

1 week
394.03
Extreme 394.0323
425.65
1 month
391.01
Extreme 391.01
425.65
Current year
391.01
Extreme 391.01
448.40
1 year
320.01
Extreme 320.01
448.40
3 years
176.36
Extreme 176.36
448.40
5 years
164.07
Extreme 164.07
448.40
10 years
63.60
Extreme 63.6
448.40
More quotes

Managers and Directors - Vertex Pharmaceuticals Incorporated

Managers TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Charles Wagner DFI
 Director of Finance/CFO 55 19-04-09
Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 17-06-07
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Bruce Sachs BRD
 Director/Board Member 64 97-12-31
More insiders

ETFs positioned on Vertex Pharmaceuticals Incorporated

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
7.67% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
7.08% 0 M€ 0.00% -
More ETFs positioned on Vertex Pharmaceuticals Incorporated

Quotes

Date Price Change Volume
24-05-10 422.8 +0.90% 1,064,604
24-05-09 419 +0.04% 676,185
24-05-08 418.8 +2.09% 1,651,673
24-05-07 410.2 +1.92% 1,614,092
24-05-06 402.5 +0.35% 1,463,611

Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT

More quotes

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
Biotechnology & Medical Research
Calendar
2024-05-15 - Annual General Meeting
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8 USD
Average target price
462.1 USD
Spread / Average Target
+9.30%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+295.70% 8.12B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW